Torpedo Therapeutics is dedicated to revolutionizing the treatment of neurological disorders through high-precision, closed-loop neuromodulation devices. Their implantable devices are designed to sense and stimulate neural activity in the brain, enhancing the efficacy and adoption of deep brain stimulation (DBS) therapy. DBS is an FDA-approved treatment for conditions such as Parkinson’s disease, essential tremor, dystonia, and drug-resistant epilepsy. Torpedo Therapeutics aims to provide a more effective and automated approach to brain therapy.
The company has developed advanced features for their devices, including high-precision stimulation, closed-loop sensing and stimulation, and automated data analysis. These innovations are intended to significantly improve patient outcomes by offering more precise and responsive treatment options. Torpedo Therapeutics' impact is marked by its commitment to advancing DBS technology and improving the quality of life for individuals with severe neurological conditions.
